Autolus logo
Startup

Autolus

See Autolus's full profile

BOOK A DEMO
Headquarters

United Kingdom

Founded Year

2018

Total Funding

$381.7M

Employees

201 - 500

Status

Active


About Autolus

Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.

Headquarters

W12 7RZ London, United Kingdom


General Information on Autolus

Brand name Autolus
Company name Autolus Therapeutics plc
Website https://www.autolus.com/
Founded year 2018
Employees 201 - 500
Founding team

Martin Pule

Contact [email protected]
+4401483920748

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about Autolus

MedGadget 18.08.2022
Cancer Cell Market Size is projected to reach US$ 14,803.5 Million by 2027, growing at a CAGR of 8.20 %: Abbott Laboratories, Novartis International AG, Arcellx, Autolus Therapeutics

Major industries aiming on acceptance from official bodies for new therapy of malignancy such as breast carcinoma and others is anticipated to fuel the global cancer cell market. For example, in 2019, Novartis, declared to gain the U.S. FDA clearance for Piqray in integration with fulvestrant for the therapy of postmenopausal females and male with HRP, HR+/HER2-, PIK3CA-mutated developed or metastatic breast carcinoma. Request Here For The ...

Autolus news
Zolmax News 18.08.2022
Autolus Therapeutics plc (NASDAQ:AUTL) Sees Large Decline in Short Interest

Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) was the target of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 1,310,000 shares, a decrease of 7.7% from the July 15th total of 1,420,000 shares. Based on an average trading volume of 167,300 shares, the short-interest ratio is currently 7.8 days. Several research analysts recently commented on the company. Needham & Company LLC ...

Autolus news
Baseball News Source 16.08.2022
Autolus Therapeutics plc (NASDAQ:AUTL) Sees Large Drop in Short Interest

Autolus Therapeutics plc ( NASDAQ:AUTL – Get Rating ) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totalling 1,310,000 shares, a drop of 7.7% from the July 15th total of 1,420,000 shares. Based on an average daily volume of 167,300 shares, the days-to-cover ratio is currently 7.8 days. Institutional Inflows and Outflows Institutional investors have recently ...

Autolus news
Nasdaq 02.08.2022
What Type Of Shareholders Own The Most Number of Autolus Therapeutics plc (NASDAQ:AUTL) Shares?

If you want to know who really controls Autolus Therapeutics plc (NASDAQ:AUTL), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership. Autolus Therapeutics is a smaller company with a market capitalization of ...

PressOracle 02.08.2022
Autolus Therapeutics (AUTL) Set to Announce Quarterly Earnings on Thursday

Autolus Therapeutics ( NASDAQ:AUTL – Get Rating ) is scheduled to issue its quarterly earnings data before the market opens on Thursday, August 4th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link Autolus Therapeutics ( NASDAQ:AUTL – Get Rating ) last announced its quarterly earnings data on Thursday, ...

Autolus news
Mayfield Recorder 06.07.2022
Pendal Group Ltd Sells 69,696 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Pendal Group Ltd reduced its holdings in shares of Autolus Therapeutics plc ( NASDAQ:AUTL – Get Rating ) by 4.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,375,106 shares of the company's stock after selling 69,696 shares during the quarter. Pendal Group Ltd's holdings in Autolus Therapeutics were worth $5,734,000 at the end of the most recent reporting ...

Autolus news
PressOracle 06.07.2022
Autolus Therapeutics plc (NASDAQ:AUTL) Position Lessened by Pendal Group Ltd

Pendal Group Ltd reduced its stake in shares of Autolus Therapeutics plc ( NASDAQ:AUTL – Get Rating ) by 4.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,375,106 shares of the company's stock after selling 69,696 shares during the period. Pendal Group Ltd owned 1.51% of Autolus Therapeutics worth $5,734,000 at the end of ...

Autolus news
FOX 40 WICZ TV 06.07.2022
Autolus Therapeutics to Participate in William Blair's Biotech Focus Conference 2022, New York, July 12 – 13, 2022

LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending William Blair's Biotech Focus Conference 2022 at The St. Regis New York in New York City. Autolus' Chief Executive Officer, Dr. Christian Itin, will participate in a panel discussion on ‘Operationalizing Cell ...

Autolus news
Stockwatch 06.07.2022
Autolus Therapeutics to Participate in William Blair's Biotech Focus Conference 2022, New York, July 12 - 13, 2022

2022-07-06 07:00 ET - News Release LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending William Blair's Biotech Focus Conference 2022 at The St. Regis New York in New York City. Autolus'Chief Executive Officer, Dr. Christian Itin, will participate in a panel discussion ...

Zolmax News 06.07.2022
Short Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Declines By 16.3%

Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 1,700,000 shares, a decrease of 16.3% from the May 31st total of 2,030,000 shares. Based on an average daily volume of 217,100 shares, the short-interest ratio is presently 7.8 days. Several institutional investors have recently bought and sold shares of AUTL. ...

Autolus news